Amgen and Horizon argue FTC's suit to block $28B merger is 'as misguided as it is unprecedented'
Amgen and Horizon Therapeutics argued on Friday that the Federal Trade Commission’s bundling claims are a “square peg in a round hole.”
The FTC filed a lawsuit in federal court last month in an attempt to block Amgen’s nearly $28 billion buyout of Horizon Therapeutics. The agency’s claims center around bundling, a scrutinized industry practice that involves offering multi-product discounts that make it difficult for rivals to compete. In an answer to the FTC’s complaint filed Friday, Amgen and Horizon said the agency’s argument is “as misguided as it is unprecedented.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
